Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Research & Development (2021 - 2025)

Historic Research & Development for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $24.2 million.

  • Kiniksa Pharmaceuticals International's Research & Development fell 725.72% to $24.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $97.5 million, marking a year-over-year increase of 103.57%. This contributed to the annual value of $111.6 million for FY2024, which is 4668.52% up from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Research & Development stood at $24.2 million for Q3 2025, which was down 725.72% from $18.8 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's 5-year Research & Development high stood at $35.2 million for Q4 2024, and its period low was $13.8 million during Q2 2022.
  • For the 5-year period, Kiniksa Pharmaceuticals International's Research & Development averaged around $21.8 million, with its median value being $20.8 million (2022).
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Research & Development crashed by 4754.49% in 2022, and later soared by 7561.84% in 2024.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Research & Development (Quarter) stood at $27.4 million in 2021, then plummeted by 47.54% to $14.4 million in 2022, then surged by 39.35% to $20.1 million in 2023, then skyrocketed by 75.62% to $35.2 million in 2024, then tumbled by 31.38% to $24.2 million in 2025.
  • Its last three reported values are $24.2 million in Q3 2025, $18.8 million for Q2 2025, and $19.3 million during Q1 2025.